Johor is set to become Asia's largest insulin hub as India's leading biotechnology firm, Biocon Ltd, invests another RM1.1 ...
The company also received tentative FDA approval for its ANDA for Rivaroxaban, an anticoagulant used to treat deep vein thrombosis, pulmonary embolism, and reduce stroke risk in nonvalvular atrial ...
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
Biocon Biologics Launches Yesintek⢠(ustekinumab-kfce) Biosimilar to Stelara® in the United States
BRIDGEWATER, N.J. and BENGALURU, India, Feb. 24, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...
This collaboration is in addition to Biocon Biologicsâ own insulin aspart drug product for the US, which is currently under ...
Biocon Ltd share price was up by 0.23% from the previous closing price of âı328.15. Who are peers of Biocon Ltd? The peers of Biocon Ltd are Sun Pharmaceuticals Industries Ltd, Divis Laboratories ...
Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.
BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback